This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus.
A one-two punch of powerful antibodies may be the best way to stop Ebola virus, reports an international team of scientists in the journal Cell. Their findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.
“This study presents results from an unprecedented international collaboration and demonstrates how 43 previously competing labs can together accelerate therapeutics and vaccine design,” says Erica Ollmann Saphire, PhD, professor at Scripps Research and director of the Viral Hemorrhagic Fever Immunotherapeutic Consortium (VIC).
From 2013–2016, West Africa faced the deadliest Ebola outbreak the world has ever seen. By the time the outbreak was declared over, 11,325 people had died. The VIC is an international group of the world’s leading virologists, immunologists, systems biologists and structural biologists working to stop an outbreak on that scale from ever striking again.
The VIC researchers aim to understand which Ebola-fighting antibodies are best—and why. The hope is that the most effective antibodies can be combined in a therapeutic “cocktail.” Unlike an Ebola vaccine, these cocktails could be given to those already infected, which is important for stopping a disease that tends to emerge unexpectedly in remote locations.
Ollmann Saphire and her colleagues in the VIC have published more than 40 studies in just the last five years. This landmark study is the first-ever side-by-side comparison of 171 antibodies against Ebola virus and other related viruses, known as filoviruses. All antibodies in the panel were donated by different labs around the world, and many had not been previously characterized in such extensive detail.
“Through the VIC, we could test a larger pool of antibodies in parallel, which increased the potential to detect statistically significant relationships between antibody features and protection,” says Saphire. “We used this global pool of antibodies to evaluate, and streamline, the research pipeline itself.”
In addition to identifying links between antibody target locations and activity, VIC researchers tested this huge pool of antibodies to reveal which antibodies “neutralized” the virus, why neutralization assays so often disagree, and whether or not neutralization in test tubes adequately predicted how well these antibodies would protect live animals from Ebola virus infection. Unexpectedly, neutralization alone was not always associated with the protective ability of an antibody.
Notably, the scientists found nine antibodies that protected mice from infection without neutralizing the virus in test tubes. These antibodies likely fight infection by interacting with an infected person’s immune system, helping orchestrate a better immune response to the virus.
This “immune effector” activity is featured in the team’s companion study published simultaneously in Cell Host & Microbe. “The ability to evoke an immune response will likely represent a new avenue of study for therapeutic antibodies for Ebola virus infection,” says Sharon Schendel, project manager for the VIC and science writer in the Saphire lab.
From the large body of results, VIC member and Scripps Research faculty member Kristian Andersen, PhD, and his graduate student Karthik Gangavarapu developed a network describing how each antibody feature correlates to protection, which can serve as a guide to predict whether newly identified antibodies will have therapeutic value. Saphire says the next steps for the VIC are to further test promising antibody cocktails in non-human primates. The team will also pursue engineering of antibodies that carry signature features to better drive immune system response.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- UN says Ebola in Congo still qualifies as global emergencyon October 18, 2019 at 6:10 pm
LONDON (AP) — The World Health Organization says the ongoing Ebola outbreak in Congo still warrants being classified as a global emergency, even though the number of confirmed cases has slowed in ...
- WIDER IMAGE-Ebola survivors battle grief and stigma in eastern Congoon October 18, 2019 at 5:12 pm
Click this link for photo essay: https://reut.rs/2nRVrha By Zohra Bensemra BUTEMBO, Democratic Republic of Congo, Oct 18 (Reuters) - A rlette Kavugho was discharged from an Ebola ward in eastern Congo ...
- Merck gets EU panel nod for first ever Ebola vaccineon October 18, 2019 at 5:08 pm
Oct 18 (Reuters) - A panel of the European drugs regulator on Friday recommended approving Merck & Co's vaccine for the deadly Ebola virus. The European Medicines Agency said https://bit.ly/2MrRw4c ...
- EU Panel's Thumbs-Up on First Ebola Vaccine a 'Triumph' for Public Healthon October 18, 2019 at 2:55 pm
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the V920 Ebola Zaire vaccine (Ervebo, Merck ), the first vaccine to protect ...
- WHO says Ebola in DR Congo still qualifies as global emergencyon October 18, 2019 at 2:44 pm
The World Health Organization (WHO) said the ongoing Ebola outbreak in the Democratic Republic of Congo still warrants being classified as a global emergency, even though the number of confirmed cases ...
- WHO: Ebola in DRC still a global public health emergencyon October 18, 2019 at 2:16 pm
A woman and child wait to receive the Ebola vaccination in Goma, Democratic Republic of the Congo. Photo by: REUTERS / Baz Ratner MANILA — The Ebola outbreak in the Democratic Republic of Congo is ...
- W.H.O. Continues Emergency Status for Ebola Outbreak in Congoon October 18, 2019 at 1:55 pm
The Ebola outbreak in the Democratic Republic of Congo is still a public health emergency and will be one for at least the next three months, the World Health Organization said on Friday. At the same ...
- UPDATE 3-WHO hails 'triumph' as Merck's Ebola vaccine gets European green lighton October 18, 2019 at 1:08 pm
[email protected] (Adds more detail, background, quote from Merck's Perlmutter) LONDON Oct 18 (Reuters) - The world's first Ebola vaccine was recommended for approval by European drugs regulators on Friday in a ...
- CORRECTED-BRIEF-WHO Welcomes EMA Recommendation Of Conditional Marketing Authorization For Merck's V920 Ebola Zaire Vaccineon October 18, 2019 at 12:11 pm
(Corrects source to “World Health Organization” from “Merck & Co Inc”) Oct 18 (Reuters) - World Health Organization: * WORLD HEALTH ORGANIZATION SAYS “WELCOMES” THE EMA ANNOUNCEMENT RECOMMENDING A ...
via Bing News